Stray Dog
EN中文
EN中文

Prices are Hyperliquid perpetual futures: contracts that track each stock and trade 24/7. They are not exchange prices and can differ from them, most of all while US markets are closed. Change is over 24 hours. For information only.

  • TSLA—
  • PLTR—
  • HIMS—
  • SPCX—
  • SOFI—
  • BTC—
…Loading prices
HIMS

After the FTC suit: 3 law firms open securities fraud investigations, a 5% dead-cat bounce on 30 Jul…

Sources (8)

The FTC case has entered a second phase, with another layer of legal risk on top. On 30 Jul, 3 shareholder-rights law firms (Glancy Prongay Wolke & Rotter, Schall Brown & Schwartz and SBS Law) opened securities fraud investigations. In the US this is the standard prelude to a securities class action after a share-price collapse.

Read more

The focus is on whether management misled investors in its disclosures on privacy compliance and billing practices, which bears more directly on the share price than the data-breach class actions already on record as of 2 May. On top of that, the 5% bounce to about $29 on 30 Jul was triggered by HIMS's official vow to fight and a bullish piece by a Seeking Alpha contributor ('FTC Panic Gift'). It is a dead-cat bounce driven by bargain hunting and short covering, and the fundamentals have not changed: all 3 FTC charges (data privacy, deceptive billing, cancellation barriers) go to the weak spot of the subscription business model. The shares are still 22% below the early-July high of $37. The sell-side consensus is a mix of Moderate Buy and Hold (4 Buy, 9-12 Hold, 2 Sell), and the average target of about $30 implies only 3% upside. The real next binary event is the Q2 results on 10 Aug: how management quantifies the actual impact of the FTC suit on subscription retention and conversion. The positive outcome of the 23-24 Jul FDA peptide advisory committee (8-6 to recommend 6 of the 7 peptides for 503A, including BPC-157, KPV and TB-500) has been completely overshadowed.

Key evidence

  • On 30 Jul the 3 law firms Glancy Prongay Wolke & Rotter, Schall Brown & Schwartz and SBS Law issued announcements one after another, opening securities fraud investigations on behalf of HIMS shareholders hurt by the FTC suit
  • Thrust of the securities class action claims: management's earlier disclosures on privacy compliance and billing practices misled investors (more directly tied to the share price than the privacy class actions already on record as of 2 May)
  • Plunged nearly 15% on 29 Jul on the FTC suit; rebounded more than 5% intraday on 30 Jul to close at about $29
  • Triggers for the bounce: HIMS's official statement that it will fight hard and that the charges are baseless, plus a bullish Seeking Alpha contributor piece, 'FTC Panic Gift' (less than 1.5x 2027 sales, targeting 2030 adjusted EBITDA of $1.3 billion)
  • At about $29, the shares are still down 22% from the early-July high of $37
  • Sell-side consensus is a Moderate Buy/Hold mix (about 4 Buy, 9-12 Hold, 2 Sell), with an average target of about $30 implying only about 3% upside
Show 2 more
  • All 3 FTC charges (data privacy, deceptive billing, cancellation barriers) go to the weak spot of the subscription business model
  • The 23-24 Jul FDA peptide advisory committee's 8-6 vote recommending 6 of the 7 peptides for 503A (including BPC-157, KPV and TB-500, which HIMS is targeting) has been completely overshadowed by the FTC suit

Catalysts to watch

  • 10 Aug Q2 results: the next binary event; management needs to quantify the actual impact of the FTC suit on subscription retention and conversion
  • Whether a securities class action is formally filed (law-firm investigations typically lead to a filing window of 30-60 days)
  • Pace of the FTC proceedings (motions, signs of settlement, temporary injunctions)
  • Timing of the formal 503A peptide list: if BPC-157, KPV and TB-500 make it, that is positive for HIMS's product pipeline

Risks

  • A securities class action filing would add legal tail costs and damage management's credibility
  • The 3 FTC charges strike at the heart of the subscription model; if upheld, they would structurally depress LTV/CAC
  • A dead-cat bounce is not a bottom: sell-side targets imply only 3% upside, so risk/reward is neutral, leaning cautious
  • If management cannot quantify the FTC impact at the 10 Aug results, or subscription metrics deteriorate, a second leg down could follow
  • The 2 data-breach class actions on record as of 2 May and the new securities fraud investigations add up to a deepening legal shadow
  • The peptide good news has been completely overshadowed by the FTC suit and cannot drive a rebound in the near term

Sources 8

  1. Glancy Prongay Wolke & Rotter, 30 Jul announcement
  2. Schall Brown & Schwartz, 30 Jul announcement
  3. SBS Law, 30 Jul announcement
  4. HIMS official statement responding to the FTC suit
  5. Seeking Alpha contributor article 'FTC Panic Gift'
  6. Sell-side consensus data (Moderate Buy/Hold split, average target about $30)
  7. The 2 data-breach class actions on record as of 2 May (for historical comparison)
  8. 23-24 Jul FDA peptide advisory committee vote

A brief is a lead for our research, not a verified conclusion or advice.